Skip to main
ALT
ALT logo

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 31%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune Inc. is positioned favorably in the biopharmaceutical landscape due to the promising clinical advancements of its product candidate, pemvidutide, which has shown significant efficacy in reducing liver fat and improving liver health markers in conditions such as metabolic-associated steatohepatitis (MASH) and alcoholic liver disease (ALD). The drug's dual mechanism of action, targeting both weight loss and direct liver effects, coupled with a favorable tolerability profile compared to existing therapies, enhances its attractiveness for treating obesity and metabolic diseases. Additionally, management's insights regarding potential non-invasive regulatory endpoints suggest a streamlined path for pemvidutide's approval process, further bolstering the company's growth prospects and potential market impact.

Bears say

Altimmune Inc reported a net loss of $23.2 million in the fourth quarter of 2024, reflecting financial challenges as the company navigates clinical development hurdles. The drug candidate pemvidutide, despite demonstrating a 15.6% average body weight loss in clinical trials, faces significant risks including potential challenges in market adoption, competition, and various commercialization hurdles that could impede growth. Additionally, the broader landscape is complicated by external factors such as capital market instability, ongoing risks from COVID-19, and geopolitical disruptions, all of which contribute to a negative outlook for the company’s stock.

Altimmune (ALT) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 31% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Buy based on their latest research and market trends.

According to 13 analysts, Altimmune (ALT) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.